EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Psychemedics's enterprise value is $15.14 Mil.
Psychemedics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.25 Mil. Therefore, Psychemedics's EV-to-EBITDA for today is -60.55.
The historical rank and industry rank for Psychemedics's EV-to-EBITDA or its related term are showing as below:
PMD'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -277.17 Med: 11.16 Max: 43.21
Current: -60.55
During the past 13 years, the highest EV-to-EBITDA of Psychemedics was 43.21. The lowest was -277.17. And the median was 11.16.
PMD's EV-to-EBITDA is ranked worse than 100% of 118
companies
in the Medical Diagnostics & Research industry
Industry Median: 15.85
vs PMD: -60.55
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Psychemedics EV-to-EBITDA Historical Data
The historical data trend for Psychemedics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Psychemedics's EV-to-EBITDA
For the Diagnostics & Research subindustry, Psychemedics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Psychemedics's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Psychemedics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Psychemedics's EV-to-EBITDA falls into.
Psychemedics EV-to-EBITDA Calculation
Psychemedics's EV-to-EBITDA for today is calculated as:
Psychemedics's current Enterprise Value is $15.14 Mil.
Psychemedics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Psychemedics (NAS:PMD) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Psychemedics's PE Ratio for today is calculated as:
Psychemedics's share price for today is $2.55.
Psychemedics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.720.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Psychemedics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Psychemedics Corp is engaged in providing testing services for the detection of drugs of abuse through the analysis of hair samples. The company operates through a single segment of drug testing services which include training for the collection of samples and storage of positive samples for its customers for an agreed-upon fee per unit testing of samples. The testing methods of the company utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. Geographically it generates the majority of its revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PMD has been successfully added to your 